News >

FDA Grants Priority Review to Frontline Nivolumab/Ipilimumab in Advanced NSCLC

Gina Columbus
Published: Wednesday, Jan 15, 2020

Sabine Maier, MD

Sabine Maier, MD

The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the first-line treatment of patients with metastatic or recurrent non–small cell lung cancer (NSCLC) that does not have EGFR or ALK genomic tumor aberrations.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication